ResearchFixed-dose, extended-release combination of naltrexone and bupropion reduces craving and body weight: A pooled post hoc analysis
ResearchReal-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States
ResearchUse of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis
ResearchIdentifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis
ResearchChanges in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study
ResearchEmployee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey
ResearchTirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial
ResearchImpact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)
ResearchPatient Perspectives on Weight Management and Wellness After Liver Transplantation: A Convergent Mixed Methods Study
ResearchImpact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)
ResearchEffects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting
ResearchApplication of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions
ResearchNutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 based therapies: An expert consensus statement using a modified Delphi approach